MicroPort® EP Successfully Performs First Procedure in Belgium

Brussels, Belgium, 07 June 2021 — A team of electrophysiologists in Belgium have successfully completed an electrophysiology (EP) procedure for atrioventricular node reentrant tachycardia using a full range of products developed by Shanghai MicroPort® EP MedTech Co., Ltd. (MicroPort® EP). The products used during the procedure, which marked the first 3D case for MicroPort® EP in the Belgian market, included Columbus 3D EP Navigation System (Columbus®), OptimAblate® Cardiac RF Generator, OptimAblate® Irrigation Pump, and FireMagic® 3D Saline Irrigated RF Ablation Catheter, along with other accessories.

The team of Belgium electrophysiologists who performed the procedure gave full credit to Columbus® for its stable performance and user-friendly interface that facilitated the procedure. The clear and consistent signal enabled by the EasyFinder® catheter was also recognized by the surgical team.

Dr. Yiyong Sun, President of MicroPort® EP, said, “As the population is aging across the world, the incidence of cardiac arrhythmias is also on the rise. In an effort to bring premium products and services to more patients with heart arrhythmia and doctors worldwide, MicroPort® EP is speeding up its presence in the global market”

The Columbus® System is primarily used for the diagnosis and treatment of complex arrhythmias. When compared with traditional catheter ablation under X-ray fluoroscopy, the Columbus® System allows for the incorporation of intracardiac electrical signals with spatial structures, helping the surgeon to better perform catheter ablation for complex arrhythmias, while significantly reducing X-ray exposure for surgeons and patients.

To date, over 20,000 procedures have been performed worldwide using Columbus®, and the products and services of MicroPort® EP are available in more than 20 countries in Europe, Oceania, Africa, South America and Asia. Recently, MicroPort® EP successfully entered into the Brazilian market, with team of local experts applying Columbus® and its ancillary catheter to successfully complete the 3D ablation cases. In future, MicroPort® EP will continue to focus on innovation and development, offering world-class total medical solutions for electrophysiological interventions so that more patients enjoy a healthy life.

About MicroPort® EP

Shanghai MicroPort EP MedTech Co., Ltd, a subsidiary of MicroPort Scientific Corporation (MicroPort®, stock code: 00853.HK), was established in the Shanghai International Medical Zone on August 31, 2010. Its concentration is on the development, manufacture, and marketing of minimally invasive medical devices for the treatment of electrophysiological diseases, including cardiac ablation catheters, diagnostic catheters, 3D navigation systems, amongst others.